Advertisement
Advertisement

RNA

RNA logo

Avidity Biosciences, Inc. Common Stock

72.59
USD
Sponsored
+0.02
+0.02%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

72.57

-0.02
-0.02%

RNA Earnings Reports

Positive Surprise Ratio

RNA beat 12 of 22 last estimates.

55%

Next Report

Date of Next Report
Feb 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
$3.38M
/
-$1.26
Implied change from Q3 25 (Revenue/ EPS)
-72.87%
/
-0.79%
Implied change from Q4 24 (Revenue/ EPS)
+13.85%
/
+57.50%

Avidity Biosciences, Inc. Common Stock earnings per share and revenue

On Nov 10, 2025, RNA reported earnings of -1.27 USD per share (EPS) for Q3 25, missing the estimate of -1.11 USD, resulting in a -14.20% surprise. Revenue reached 12.47 million, compared to an expected 1.95 million, with a 539.26% difference. The market reacted with a +1.23% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of -1.26 USD, with revenue projected to reach 3.38 million USD, implying an decrease of -0.79% EPS, and decrease of -72.87% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Avidity Biosciences, Inc. Common Stock reported EPS of -$1.27, missing estimates by -14.2%, and revenue of $12.47M, 539.26% above expectations.
The stock price moved up 1.23%, changed from $69.84 before the earnings release to $70.70 the day after.
The next earning report is scheduled for Feb 25, 2026.
Based on 14 analysts, Avidity Biosciences, Inc. Common Stock is expected to report EPS of -$1.26 and revenue of $3.38M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement